Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.

doi:10.1016/j.lungcan.2026.109337

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2026

Bartolomeo Valentina, Jongbloed Mandy, Huijs Jarno W J, Filippi Andrea Riccardo, van den Borne Ben E E M, Pitz Cordula, Gietema Hester, Degens Juliette, Youssef-El Soud Magdolen, Steens Michelle, Dursun Safiye, van Geffen Wouter H, de Boer Peter, De Ruysscher Dirk K M, Hendriks Lizza E L

Abstract excerpt

Oligoprogressive disease (OPD) occurs when a limited number of disease sites show progression. Data on OPD incidence during systemic therapy for metastatic non-small cell lung cancer (NSCLC) are increasing, while data on progression patterns after systemic therapy with local radical treatment (LRT) in patients with synchronous oligometastatic disease (sOMD) are limited. We conducted a retrospective multicenter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Disease Progression

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 41720018
DOI: 10.1016/j.lungcan.2026.109337

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment.PMID 41720018Read ↗

Distinct metastatic organotropism shapes prognosis in lung adenocarcinoma with brain metastasisSemantic proximity Read ↗

Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib.Semantic proximity Read ↗

Progression phenotypes to anti-PD-(L)1 therapy and subsequent management of patients with metastatic NSCLC: A real-world cohort study.Semantic proximity Read ↗

Evaluation of the Updated 2022 Lung-GPA in NSCLC Adenocarcinoma Patients with Brain Metastases: Analysis of Prognostic Factors in a German Clinical CohortSemantic proximity Read ↗

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.Semantic proximity Read ↗

Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact® survey 2021.Semantic proximity Read ↗

Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival.Semantic proximity Read ↗

Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

A Single Center Experience in Combined Oncological-Surgical Treatment for Resectable Locally-Advanced Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read ↗

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.Semantic proximity Read ↗

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 InhibitorsSemantic proximity Read ↗

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.